Nav1.7 is a voltage-gated sodium channel encoded by the gene SCN9A, and it sits at the crossroads of two extraordinary human conditions: people born completely unable to feel pain, and people trapped in states of relentless, excruciating pain. Mutations that shut this channel down produce lifelong painlessness, while mutations that crank up its activity cause burning extremities and spontaneous pain attacks. The channel has become one of the most intensely studied targets in pain research, not because it is the only sodium channel involved in pain signaling, but because its genetic track record in humans makes the case that it is a master regulator of whether pain signals get through.
Where Nav1.7 Lives and What It Does
Nav1.7 is found predominantly in the peripheral nervous system. It is expressed at high levels in the sensory neurons of the dorsal root ganglia and trigeminal ganglia, which are the relay stations for touch, temperature, and pain signals traveling from your body to your spinal cord and brain. It also shows up in sympathetic ganglion neurons, which control involuntary functions like blood vessel constriction and sweating.1Neuron. Nav1.7: The Channel for Extreme Pain and Pain-Free Life This peripheral address is important. Other sodium channel subtypes are concentrated in the brain, spinal cord, heart, or skeletal muscle. Nav1.7’s home turf is the sensory nerve endings where pain begins.
The channel’s job is to help initiate and propagate electrical signals, known as action potentials, along sensory nerve fibers. When you stub your toe, Nav1.7 opens in response to a small voltage change at the nerve ending, allowing sodium ions to rush in and amplify the signal enough for larger sodium channels to fire and relay the message toward the spinal cord. In mice engineered to lack Nav1.7 in their sensory neurons, nerve conduction velocity dropped by about 20%, and the neurons struggled to fire rapid successive signals.2PubMed Central. NaV1.7 and pain: contribution of peripheral nerves Nav1.7 acts less like the main engine and more like the spark plug: it sets the threshold for whether pain neurons fire in the first place.
This threshold-setting role is where Nav1.7 interacts with another sodium channel, Nav1.8, which carries the bulk of the current during a pain neuron’s action potential. Computer simulations have shown that increasing Nav1.7 expression lowers the current needed to trigger firing and amplifies subthreshold oscillations, boosting repetitive firing in neurons that also express Nav1.8.3PubMed Central. Physiological interactions between Na(v)1.7 and Na(v)1.8 sodium channels: a computer simulation study The two channels function as partners, with Nav1.7 deciding whether the pain neuron wakes up and Nav1.8 carrying the signal once it does.
Born Without Pain
The most dramatic evidence for Nav1.7’s role came from families identified in Pakistan in the mid-2000s. Researchers traced a cluster of individuals who had never felt pain in their lives to a homozygous stop-codon mutation in SCN9A, the gene encoding Nav1.7, which truncated the protein and made it completely nonfunctional.4Human Molecular Genetics. A stop codon mutation in SCN9A causes lack of pain sensation These individuals could feel touch, pressure, and temperature, but noxious stimuli that would cause agony in anyone else simply did not register as painful. The condition, called channelopathy-associated insensitivity to pain (CIP), requires both copies of the gene to carry loss-of-function mutations.5PubMed Central. Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations
Living without pain sounds appealing until you see its consequences. Pain is a protective alarm system, and people born without it accumulate injuries relentlessly. Clinical case reports describe children with CIP who chew their tongues and lips to the point of amputation, destroy their fingertips through repeated trauma, and develop chronic wound infections in their limbs because they never notice injuries that would make others recoil.6PubMed Central. Congenital Insensitivity to Pain without Anhidrosis: Orodental Problems and Management Several of the originally studied Pakistani individuals died young from injuries sustained during street performances, where they walked on coals or stabbed themselves, seemingly invulnerable.
The Anosmia Connection
Loss-of-function Nav1.7 mutations do not only eliminate pain. They also eliminate the sense of smell. This was an unexpected finding that initially puzzled researchers, since olfaction and pain seem unrelated. It turns out Nav1.7 is also expressed in olfactory sensory neurons, which detect odors in the nose. In mice and humans lacking functional Nav1.7, these neurons can still detect odors and generate action potentials in response, but they fail to release neurotransmitters at their synaptic terminals in the olfactory bulb.7PubMed Central. Loss-of-function mutations in sodium channel Nav1.7 cause anosmia The signal dies at the first relay point.
The mechanism appears to involve calcium entry at nerve terminals. Nav1.7 is thought to be needed for a voltage-dependent influx of calcium ions at presynaptic terminals in olfactory neurons, and without it, vesicles loaded with the neurotransmitter glutamate simply do not get released.8JAMA Neurology. Link Between Pain and Olfaction in an Inherited Sodium Channelopathy Anosmia in CIP patients is essentially complete, and it has become a clinical hallmark. If someone claims to have pain insensitivity from Nav1.7 mutations and they can still smell normally, the diagnosis is probably wrong.
The Body’s Own Painkiller Response
For years, researchers assumed that pain insensitivity from Nav1.7 loss was simply a wiring problem: no channel, no signal. But a surprising discovery showed the story is more complex. Mice and humans lacking Nav1.7 produce abnormally high levels of endogenous opioids, the body’s own morphine-like molecules. Specifically, sensory neurons in Nav1.7 knockout animals show a dramatic upregulation of enkephalin precursor genes, leading to elevated levels of met-enkephalin protein.9PubMed Central. Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7
When the opioid blocker naloxone was given to Nav1.7 knockout mice, their pain insensitivity was dramatically reduced, and the same was observed in a human with a confirmed Nav1.7 null mutation.9PubMed Central. Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7 That result was striking: it meant the painlessness was not purely from a broken wire. The body was actively suppressing pain through its own opioid system. Follow-up work pinpointed the specific receptors involved, showing that mu-opioid and delta-opioid receptors together account for the opioid-mediated analgesia, while kappa-opioid receptors play no significant role.10PubMed Central. Analgesia linked to Nav1.7 loss of function requires µ- and δ-opioid receptors
The picture grew richer still when researchers looked at signaling beyond opioids alone. Without Nav1.7, the balance between pain-promoting and pain-suppressing receptor signaling inside sensory neurons shifts. The effectiveness of serotonin-driven pain-promoting pathways decreases, while mu-opioid receptor signaling becomes more efficient at shutting down the residual sodium currents that other channels still produce.11PubMed Central. Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice Nav1.7 loss does not just silence a single channel. It rewires the cell’s internal signaling balance toward a state of built-in analgesia.
Gain-of-Function Mutations and Extreme Pain
If losing Nav1.7 means no pain, gaining extra Nav1.7 activity means too much. Gain-of-function mutations in SCN9A cause at least three recognized pain conditions, each with a distinct mechanism tied to how the channel misbehaves.
In inherited erythromelalgia (IEM), mutations shift Nav1.7’s activation to more negative (hyperpolarized) voltages, meaning the channel opens too easily. In nociceptors derived from patients carrying the I848T mutation, the voltage at which the channel activates shifted by about 6 to 7 millivolts in the hyperpolarized direction compared to healthy controls, enough to lower the action potential threshold and make pain neurons fire when they should not.12PubMed Central. The role of Na v 1.7 in human nociceptors: insights from human induced pluripotent stem cell–derived sensory neurons of erythromelalgia patients Another erythromelalgia mutation, L823R, produces an even more dramatic shift of roughly 15 millivolts, by introducing an extra positive charge directly into the voltage-sensing region of the channel.13Biochemical and Biophysical Research Communications. Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials People with erythromelalgia experience episodes of burning pain, redness, and warmth in their hands and feet, often triggered by mild warming or exercise. Some are remarkably resistant to lidocaine, a common local anesthetic. One erythromelalgia-associated mutation, N395K, required roughly five to six times higher lidocaine concentrations to achieve the same degree of channel block as the normal channel.14PubMed Central. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity
Paroxysmal extreme pain disorder (PEPD) involves a different type of channel malfunction. Rather than opening too easily, the channel fails to inactivate properly. All characterized PEPD mutations destabilize fast inactivation, producing persistent sodium currents that keep flowing long after the channel should have shut itself off.15Neuron. SCN9A Mutations in Paroxysmal Extreme Pain Disorder: Allelic Variants Underlie Distinct Channel Defects and Phenotypes The mutations cluster in regions of the channel critical for the fast inactivation gate, and the resulting persistent currents keep pain neurons firing long after the initial stimulus is gone.16PubMed Central. Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation PEPD manifests as sudden attacks of severe rectal, ocular, or jaw pain, often in infants, and can be accompanied by skin flushing and brief loss of consciousness.
A third condition, idiopathic small fiber neuropathy (I-SFN), was more recently linked to Nav1.7. In a study of patients who met strict diagnostic criteria for I-SFN, about 29% carried novel gain-of-function mutations in SCN9A, each of which made dorsal root ganglion neurons hyperexcitable in the lab.17PubMed. Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy This finding extended Nav1.7’s clinical relevance well beyond the rare inherited syndromes and suggested it plays a role in more common neuropathic pain conditions where small nerve fibers degenerate.
How Inflammation Supercharges Nav1.7
You do not need a genetic mutation for Nav1.7 to cause trouble. Inflammation can modify the channel’s behavior through phosphorylation, a chemical process where enzymes tack phosphate groups onto the channel protein and change how it responds to voltage. Researchers studying the erythromelalgia mutation I848T found that much of the abnormal voltage shift that makes the channel open too easily is driven by phosphorylation by an enzyme called protein kinase C (PKC). When they blocked PKC with a selective inhibitor, the abnormal shift was almost entirely abolished, restoring near-normal channel behavior.18Journal of Biological Chemistry. Phosphorylation of a chronic pain mutation in the voltage-gated sodium channel Nav1.7 increases voltage sensitivity
This matters because PKC activity spikes during inflammation. It implies that even a mildly predisposing Nav1.7 variant could become clinically painful when the surrounding tissue is inflamed, and that the same mutation might cause minimal symptoms at rest but flare during injury or illness. Beyond phosphorylation, Nav1.7-driven sodium influx in pain neurons can trigger secondary cascades: in cancer-induced bone pain models, Nav1.7 activity promotes calcium overload and activates inflammatory signaling pathways inside the neurons themselves, creating a feedback loop where the channel contributes to both pain signaling and neuroinflammation.19PubMed Central. Synergistic Inhibition of Nav1.7 and NCX 1: A Novel Strategy for Treating Cancer‐Induced Bone Pain by Modulating Pain Sensitization and Neuronal Inflammation
Why Drug Development Has Been So Difficult
The genetic evidence makes Nav1.7 look like a perfect drug target: block it, and you should get pain relief without the addiction risk of opioids or the cognitive effects of drugs that act in the brain. The pharmaceutical industry has poured enormous resources into this idea since the mid-2000s, and the results have been consistently disappointing. Several selective Nav1.7 inhibitors that worked well in animal models failed to provide meaningful pain relief in human clinical trials.
The core challenge is selectivity. Mammals have nine sodium channel subtypes, and they share high sequence identity.20PubMed. Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist Nav1.5 controls the heartbeat. Nav1.4 drives skeletal muscle contraction. Nav1.1 and Nav1.2 are essential for brain function. A drug that blocks Nav1.7 but also hits any of these others at therapeutic doses would cause dangerous side effects. Achieving the needed selectivity among channels that share so much structural similarity has proven extremely difficult.21PubMed Central. Discovery of Selective Inhibitors of NaV1.7 Templated on Saxitoxin as Therapeutics for Pain
Even when selectivity was achieved in the lab, clinical translation stumbled for other reasons. One prominent candidate, PF-05089771, failed in clinical trials partly because the oral dose needed to actually occupy enough Nav1.7 channels in humans turned out to be far higher than what worked when injected directly into rodents.22PubMed Central. Discordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain The mismatch between preclinical and clinical dosing regimens may explain why multiple companies independently saw promising animal data evaporate in human trials. The channel is the right target, but reaching it effectively in living people remains an unsolved problem for small-molecule drugs.
Tarantula Toxins and Structural Insights
Some of the most informative advances in understanding Nav1.7 have come from studying spider venoms. Tarantulas produce peptide toxins that have been selectively targeting voltage-gated sodium channels for millions of years, and two of these, ProTx-II from the Peruvian green velvet tarantula and HwTx-IV from a Chinese bird spider, have become essential research tools.
Cryo-electron microscopy and X-ray crystallography have revealed how these toxins work. ProTx-II positions two positively charged amino acids into the extracellular vestibule of Nav1.7’s second voltage-sensor domain, physically blocking the upward movement of the S4 helix that is required for the channel to open. The toxin traps the voltage sensor in a deactivated (resting) state, with the S4 helix pushed roughly 10 angstroms downward compared to its activated position.23Cell. Structural Basis of Nav1.7 Inhibition by a Gating-Modifier Spider Toxin A modified version of HwTx-IV achieves something similar, inserting a lysine residue like a “stinger” into a cluster of negatively charged amino acids in the same region.24PubMed Central. Structural Basis for High-Affinity Trapping of the NaV1.7 Channel in its Resting State by Tarantula Toxin
Binding of these toxins also triggers a structural change in the channel’s pore region: the S6 helix in domain IV transitions from a standard alpha-helix to a pi-helix, which reshapes the site where the channel’s own fast-inactivation gate docks.25Cell Reports. High-resolution structures of human Nav1.7 reveal gating modulation through α-π helical transition of S6IV These structural details give drug designers a molecular blueprint: rather than trying to plug the channel’s pore directly, which is where all those hard-to-distinguish sodium channels look nearly identical, the goal is to target the voltage-sensor regions where Nav1.7 has more unique features. The spider toxins have essentially shown the industry where to aim.
Gene Therapy Approaches
Given the difficulty of designing selective small-molecule Nav1.7 blockers, some researchers have turned to gene-level strategies. One approach uses epigenome editing, delivering modified CRISPR machinery to sensory neurons that does not cut the DNA but instead silences the SCN9A gene by adding chemical marks that repress its expression. In mice, this approach reduced Nav1.7 levels in lumbar dorsal root ganglia and produced long-lasting pain relief in both inflammatory and neuropathic pain models without affecting normal motor function.26PubMed Central. Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice
The appeal of this strategy is that it mimics the natural human knockout more faithfully than a drug can. Instead of transiently blocking the channel for a few hours, it dials down production of the channel protein in the relevant neurons for an extended period. The researchers termed the approach “pain LATER” (long-lasting analgesia via targeted epigenetic repression). It remains early-stage and far from human use, but it sidesteps the selectivity problem entirely: you are not trying to distinguish Nav1.7 from Nav1.5 at the protein level, because the genetic sequence that encodes each is unique enough to target precisely.
The Naked Mole-Rat’s Natural Experiment
Humans are not the only species where Nav1.7 variation shapes pain. The naked mole-rat, a subterranean rodent known for its extreme tolerance to harsh conditions, carries a species-specific variant of Nav1.7 that renders it insensitive to acid-induced pain.27PubMed. The molecular basis of acid insensitivity in the African naked mole-rat This matters because these animals live in crowded underground burrows with high carbon dioxide levels, which would cause tissue acidosis. In most mammals, acidosis activates Nav1.7 and triggers pain. In naked mole-rats, the altered Nav1.7 is instead potently blocked by protons, so rising acid levels actually shut the channel down rather than turning it on.28PubMed Central. Extreme Physiology Extreme Tolerance to Hypoxia, Hypercapnia, and Pain in the Naked Mole-Rat
Evolutionary pressure essentially flipped the channel’s response to its environment. The naked mole-rat still has a fully functional Nav1.7 for normal pain signaling in other contexts; it has not lost pain sensation entirely the way human CIP patients have. Instead, a targeted mutation tipped the balance so that proton-induced excitation becomes proton-induced inhibition, eliminating acid pain without compromising the rest of the pain alarm system. From a drug-design perspective, this is tantalizing. It shows that you do not necessarily need to block Nav1.7 completely to get meaningful pain relief. A drug that shifted the channel’s behavior in a context-specific way, dampening it under inflammatory or acidic conditions while leaving normal pain detection intact, would be closer to what the mole-rat achieved through natural selection than to what a simple channel blocker does.
Why the Opioid Link Changes the Strategy
The discovery that Nav1.7 loss triggers endogenous opioid production has practical implications that go beyond basic science. It suggests that a Nav1.7 blocker used alone might not replicate the full pain relief seen in people born without the channel, because simply blocking sodium flow through Nav1.7 would not necessarily trigger the compensatory opioid surge that develops over a lifetime of absent Nav1.7 signaling. Some researchers have proposed that a combination therapy, pairing a Nav1.7 inhibitor with a low-dose opioid, could more faithfully mimic the natural knockout state. The opioid component might amplify pain relief at doses too low to cause the dependence and respiratory depression associated with conventional opioid prescribing.
Whether this combination approach will work in practice remains to be tested rigorously in humans. But it offers a conceptual framework for why pure Nav1.7 blockade in clinical trials may have underperformed: the drug companies were reproducing only half of the biology. The channel itself was being blocked, but the downstream gene-expression changes that produce natural analgesia in CIP patients take much longer to develop and may require sustained, near-complete loss of Nav1.7 function rather than the partial, intermittent inhibition a pill provides.